Direction
Buy
Sell
Types
LMT Order
Price
QTY
Amount
--
RARE Ultragenyx Pharmaceutical
45.890-1.750-3.67%
Trading Session
02/08 11:49 ET
High
47.650
Open
47.650
Turnover
4.26M
Low
45.715
Pre Close
47.640
Volume
91.75K
Intraday
5D
1D
1W
1M
1Q
1Y
Price Forecast
News
Comment
Ultragenyx Pharmaceutical (NASDAQ:RARE) Upgraded to Hold at StockNews.com
StockNews.com upgraded shares of Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) from a sell rating to a hold rating in a research report report published on Tuesday. Several other research firm
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) to Post FY2022 Earnings of ($9.22) Per Share, Jefferies Financial Group Forecasts
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) – Research analysts at Jefferies Financial Group upped their FY2022 earnings per share estimates for Ultragenyx Pharmaceutical in a researc
Russell Investments Group Ltd. Makes New $3.86 Million Investment in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Russell Investments Group Ltd. bought a new position in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) in the 3rd quarter, according to its most recent filing with the Securities and Exch
Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target Cut to $95.00
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) had its price target dropped by investment analysts at Morgan Stanley from $100.00 to $95.00 in a research report issued to clients and investors
Ultragenyx Pharmaceutical (NASDAQ:RARE) Given New $95.00 Price Target at Morgan Stanley
Ultragenyx Pharmaceutical (NASDAQ:RARE – Get Rating) had its target price lowered by Morgan Stanley from $100.00 to $95.00 in a report published on Friday, Benzinga reports. The firm currently has an
Brokers Issue Forecasts for Ultragenyx Pharmaceutical Inc.'s Q4 2023 Earnings (NASDAQ:RARE)
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) – Equities research analysts at Jefferies Financial Group issued their Q4 2023 earnings per share (EPS) estimates for Ultragenyx Pharmaceuti
Ultragenyx Pharma Is Maintained at Overweight by Morgan Stanley
Ultragenyx Pharma Is Maintained at Overweight by Morgan Stanley
Ultragenyx Pharma Price Target Cut to $95.00/Share From $100.00 by Morgan Stanley
Morgan Stanley Maintains Overweight on Ultragenyx Pharmaceutical, Lowers Price Target to $95
Morgan Stanley analyst Jeffrey Hung maintains Ultragenyx Pharmaceutical (NASDAQ:RARE) with a Overweight and lowers the price target from $100 to $95.
Teacher Retirement System of Texas Acquires 11,514 Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)
Teacher Retirement System of Texas raised its holdings in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE – Get Rating) by 111.6% during the 3rd quarter, according to its most recent filing with the Sec
Company Overview
More
Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, engaged in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its products include Mepsevii and Crysvita. Mepsevii is an intravenous enzyme replacement therapy, which is used for the treatment of Mucopolysaccharidosis VII. Crysvita is an antibody administered via subcutaneous injection used for the treatment of XLH. The company was founded by Emil D. Kakkis on April 22, 2010, and is headquartered in Novato, CA.
CEO： Dr. Emil D. Kakkis,M.D.
Market： NASDAQ
Listing Date： 01/31/2014
Paper Trade
More
Hot List
TradeSearchNews
SymbolLatest price%Chg
Loading...
Watchlist
No Stock Yet